Condition

Schizophreniform Disorders

ClinicalTrials.gov condition label

Clinical trials43
Recruiting3
Common interventions25
Lead sponsors shown15

Clinical trials

43 shown
REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)NCT07006935 · 2026-08-30
RECRUITING
iTBS to Enhance Social Cognition in People With PsychosisNCT06118268 · 2023-04-18
RECRUITING
Bazedoxifene -Treatment for Women With SchizophreniaNCT04113993 · 2019-10-07
RECRUITING
Shared Decision Making for Antipsychotic MedicationsNCT05416658 · 2027-01-01
NOT_YET_RECRUITING
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderNCT07116694 · 2025-06-19
COMPLETED
Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early SchizophreniaNCT03974620 · 2024-12-01
UNKNOWN
Young Adults With Violent Behavior During Early Psychosis (Aim 2)NCT05756855 · 2024-03-19
COMPLETED
Investigating the Muscarinic System in Schizophrenia Using Positron Emission TomographyNCT06278246 · 2024-03-11
ACTIVE_NOT_RECRUITING
REWRITALIZE Your Recovery - Evaluation of a Creative Writing Group InterventionNCT06251908 · 2024-02-12
ACTIVE_NOT_RECRUITING
Horyzons: Implementation and Integration in Clinical PracticeNCT06002958 · 2024-01-08
TERMINATED
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar DisorderNCT06041646 · 2023-10-02
COMPLETED
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency DepartmentNCT05974527 · 2023-09-01
WITHDRAWN
EPI-MINN: Targeting Cognition and Motivation - NationalNCT05877716 · 2023-05-30
ACTIVE_NOT_RECRUITING
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)NCT05658510 · 2022-11-21
COMPLETED
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum DisordersNCT06423651 · 2022-09-01
UNKNOWN
Remote State Representation in Early PsychosisNCT05538832 · 2022-07-27
COMPLETED
Academic-Community EPINET (AC-EPINET)NCT04497857 · 2022-03-16
COMPLETED
Peripheral Immune System in Individuals With SchizophreniaNCT05109065 · 2021-03-01
COMPLETED
Horyzons: Implementation in Clinical PracticeNCT04673851 · 2021-01-19
COMPLETED
Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum DisordersNCT04418011 · 2020-11-30
COMPLETED
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis InterventionNCT04298450 · 2020-09-21
COMPLETED
Safety and Efficacy of Virtual Reality Mindfulness in Patients With PsychosisNCT05784948 · 2020-04-08
COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaNCT04268303 · 2020-01-24
COMPLETED
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in PsychosisNCT04004416 · 2020-01-16
COMPLETED
Early Psychosis Intervention - Spreading Evidence-based TreatmentNCT03919760 · 2020-01-03
COMPLETED
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control TrialNCT04173572 · 2019-12-20
COMPLETED
Estradiol as add-on to AntipsychoticsNCT04093518 · 2019-12-02
UNKNOWN
Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.NCT03510741 · 2019-01-01
COMPLETED
Mindfulness Psychoeducation Program for SchizophreniaNCT03632278 · 2018-06-03
UNKNOWN
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderNCT03187769 · 2017-06-08
COMPLETED
Minnesota Community-Based Cognitive Training in Early PsychosisNCT03079024 · 2017-05-19
COMPLETED
Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness TherapyNCT03067311 · 2016-10-03
COMPLETED
Research Into Antipsychotic Discontinuation and Reduction TrialNCT03559426 · 2016-03-24
COMPLETED
Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform DisorderNCT03848234 · 2015-12-04
COMPLETED
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in SchizophreniaNCT01082588 · 2010-06-01
COMPLETED
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With SchizophreniaNCT00595504 · 2008-01-01
COMPLETED
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With SchizophreniaNCT00407277 · 2007-02-01
COMPLETED
A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderNCT00796081 · 2006-01-01
COMPLETED
A Comparative Study of New Medications for Psychosis in AdolescentsNCT00222495 · 2002-08-01
COMPLETED
Functional Brain Activation Patterns in Schizophrenia, Measured Before and After TreatmentNCT00161057 · 2001-12-01
COMPLETED
Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic PatientsNCT00515489 · 2001-11-01
TERMINATED
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and AntioxidantsNCT00419146 · 2001-09-01
COMPLETED
Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode PsychosisNCT00157313 · 1998-01-01
UNKNOWN

Common interventions

PlaceboDRUG5EstradiolDRUG2Horyzons USADEVICE2olanzapineDRUG2RisperidoneDRUG2Sublingual film containing dexmedetomidine (BXCL501)DRUG2Treatment as UsualBEHAVIORAL2Active SMS InterventionBEHAVIORAL1adapted behavioral interventionBEHAVIORAL1ALKS 3831DRUG1Antipsychotic MaintenanceDRUG1Antipsychotic ReductionDRUG1Bazedoxifene AcetateDRUG1Blood WorkDIAGNOSTIC_TEST1BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training ParadigmDEVICE1BrainHQ Computerized Cognitive Training - Visual Perception Training ParadigmDEVICE1BXCL501DRUG1BXCL501 Sublingual FilmDRUG1Clubhouse Model of Psychosocial Rehabilitation for Serious Mental IllnessBEHAVIORAL1Cognitive and Social Cognitive TrainingDEVICE1Cognitive Remediation (REHACOP)BEHAVIORAL1Cognitive Remediation TherapyBEHAVIORAL1Coordinated Specialty Care (CSC)OTHER1Coordinated Specialty Care for First Episode PsychosisOTHER1COVID ScreeningDIAGNOSTIC_TEST1

Trial status mix

COMPLETED28
UNKNOWN5
ACTIVE_NOT_RECRUITING3
RECRUITING3
TERMINATED2
NOT_YET_RECRUITING1
WITHDRAWN1

Phase mix

NA22
PHASE47
PHASE36
PHASE23
EARLY_PHASE11
PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.